Ocular Therapeutix Drug Patent Portfolio
Ocular Therapeutix owns 1 orange book drug protected by 6 US patents Given below is the list of Ocular Therapeutix's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12144889 | Methods of treating allergic conjunctivitis | 26 Apr, 2041 | Active |
| US11458041 | Punctal plug and bioadhesives | 16 Nov, 2037 | Active |
| US12150896 | Punctal plug and bioadhesives | 07 Oct, 2036 | Active |
| US8409606 | Drug delivery through hydrogel plugs | 14 May, 2030 | Active |
| US8563027 | Drug delivery through hydrogel plugs | 12 Feb, 2030 | Active |
| US9254267 | Composite hydrogel drug delivery systems | 11 Sep, 2024 | Expired |
Latest Legal Activities on Ocular Therapeutix's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ocular Therapeutix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Oct, 2022 | US11458041 |
|
Recordation of Patent Grant Mailed
Critical
| 04 Oct, 2022 | US11458041 |
|
Email Notification
Critical
| 15 Sep, 2022 | US11458041 |
|
Issue Notification Mailed
Critical
| 14 Sep, 2022 | US11458041 |
| Dispatch to FDC | 30 Aug, 2022 | US11458041 |
|
Application Is Considered Ready for Issue
Critical
| 30 Aug, 2022 | US11458041 |
|
Issue Fee Payment Verified
Critical
| 26 Aug, 2022 | US11458041 |
|
Issue Fee Payment Received
Critical
| 26 Aug, 2022 | US11458041 |
|
Electronic Review
Critical
| 02 Aug, 2022 | US11458041 |
|
Email Notification
Critical
| 02 Aug, 2022 | US11458041 |
|
Mail Notice of Allowance
Critical
| 02 Aug, 2022 | US11458041 |
|
Notice of Allowance Data Verification Completed
Critical
| 29 Jul, 2022 | US11458041 |
| Date Forwarded to Examiner | 21 Jul, 2022 | US11458041 |
|
Information Disclosure Statement considered
Critical
| 13 Jul, 2022 | US11458041 |
| Interview Summary - Applicant Initiated - Telephonic | 13 Jul, 2022 | US11458041 |
Ocular Therapeutix's Drug Patent Litigations
Ocular Therapeutix's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 20, 2012, against patent number US9254267. The petitioner , challenged the validity of this patent, with Amarpreet S. Sawhney as the respondent. Click below to track the latest information on how companies are challenging Ocular Therapeutix's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9254267 | August, 2012 |
Decision
(23 Jul, 2015)
| Amarpreet S. Sawhney | |
Ocular Therapeutix's Family Patents
Ocular Therapeutix Drug List
Given below is the complete list of Ocular Therapeutix's drugs and the patents protecting them.
1. Dextenza
Dextenza is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12144889 | Methods of treating allergic conjunctivitis |
26 Apr, 2041
(15 years from now)
| Active |
| US11458041 | Punctal plug and bioadhesives |
16 Nov, 2037
(12 years from now)
| Active |
| US12150896 | Punctal plug and bioadhesives |
07 Oct, 2036
(11 years from now)
| Active |
| US8409606 | Drug delivery through hydrogel plugs |
14 May, 2030
(5 years from now)
| Active |
| US8563027 | Drug delivery through hydrogel plugs |
12 Feb, 2030
(4 years from now)
| Active |
| US9254267 | Composite hydrogel drug delivery systems |
11 Sep, 2024
(7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dextenza's drug page